Hemostemix Inc. Stock

HEM

CA4236943060

Biotechnology & Medical Research

Market Closed - Toronto S.E. 02:57:21 11/09/26 am AEST			5-day change	1st Jan Change
0.0750 ^CAD	0.00%		0.00%	-16.67%

01/09	Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
21/08	Hemostemix Commercializes Its Vascular Dementia Clinical Trial of Vescell(Tm) Under Larta	CI

News in other languages : Hemostemix Inc.

11/02/25	Hemostemix : Casino auf gold
15/01/25	Hemostemix: Klininsche Studien bescheinigen bahnbrechende Stammzelltherapie
23/04/21	Hemostemix : (German Translation) Hemostemix gibt den Abschluss der Nachbeobachtung von Studienteilnehmern der klinischen Phase-II-Studie bekannt und Uplisting von HMTXF
10/04/21	Hemostemix : (German Translation – April 8, 2021)

More news

Managers and Directors : Hemostemix Inc.

Manager	Title	Age	Since
Thomas Smeenk CEO	Chief Executive Officer	-	10/02/2020
Christina Wu DFI	Director of Finance/CFO	-	05/03/2020
Fraser Henderson CTO	Chief Tech/Sci/R&D Officer	-	14/10/2021

Director	Title	Age	Since
Thomas Smeenk BRD	Director/Board Member	-	26/11/2019
Ronnie Hershmann BRD	Director/Board Member	67	09/02/2020
Loran Swanberg BRD	Director/Board Member	-	08/04/2020

More insiders

Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patientâ€™s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patientâ€™s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
10/09/26	CAD 0.0750	0.00%	15,911
09/09/26	CAD 0.0750	0.00%	2,000
08/09/26	CAD 0.0750	0.00%	1,653
04/09/26	CAD 0.0750	0.00%	2,777
03/09/26	CAD 0.0750	+7.14%	2,978

Delayed Quote Toronto S.E.

More quotes

Market Cap	15.86M 11.48M 9.87M 9.31M 8.48M 1.1B 16M 111M 42.68M 557M 43.09M 42.15M 1.77B	P/E 2024	-4.36x	P/E 2025	-3.12x
Enterprise Value	18.72M 13.55M 11.65M 10.99M 10.01M 1.3B 18.89M 131M 50.38M 657M 50.87M 49.76M 2.09B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	83.37%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Toronto S.E.	HEM	Delayed
OTC Markets	HMTXF	Delayed
Deutsche Boerse AG	2VF0	Delayed
Börse Stuttgart	2VF0	Delayed
Tradegate	2VF0	Real-time

01/09	Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
21/08	Hemostemix Commercializes Its Vascular Dementia Clinical Trial of Vescell(Tm) Under Larta	CI
01/08	Hemostemix Raises C$322,250 From Second Tranche of Private Placement	MT
09/07	Hemostemix Files Commercialization Application for Treatment of Vascular Dementia, Refractory Angina and Pain	MT
27/06	Hemostemix Raises C$360,000 in the First Tranche of Private Placement of Share Units	MT
17/06	Hemostemix Inc. amended terms of the transaction	CI
30/05	Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
26/05	Hemostemix Inc. Announces the Appointment of Desire´e Cox to Board of Directors	CI
21/05	Hemostemix Inc. announced that it expects to receive CAD 1 million in funding	CI
01/05	Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01/05	Hemostemix Inc. Auditor Raises 'Going Concern' Doubt	CI
19/03	Hemostemix Inc. announced that it has received CAD 0.783968 million in funding	CI
17/01	Hemostemix Receives FDA Support for Its Basket Protocol Approach	MT

20/08	Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA	NE
13/08	Hemostemix : Dr. Ernst von Schwarz named PI of Hemostemix Longevity Clinical Trial	PU
12/08	Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial	NE
29/07	Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results	NE
23/07	Hemostemix : grants 6,280,000 options	PU

1 month	+15.38%
3 months	+36.36%
6 months	-6.25%
Current year	-16.67%

Hemostemix Inc. Stock

Stocks

HEM

CA4236943060

Biotechnology & Medical Research

Valuation : Hemostemix Inc.

Chart: Hemostemix Inc.

Latest news : Hemostemix Inc.

Press Releases : Hemostemix Inc.

News in other languages : Hemostemix Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Hemostemix Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 week	0.08	0.08
1 month	0.06	0.08
Current year	0.04	0.11
1 year	0.04	0.12
3 years	0.04	0.42
5 years	0.04	0.42
10 years	0	5

Date	Insider	Type	Main position	Quantity	% Market Cap.
30/7/26	Peter Lacey	Option	Chairman	525,000	0.2654%
22/7/26	Loran Swanberg	Option	Director	385,000	0.1946%
22/7/26	Thomas Smeenk	Option	Founder	1,730,000	0.8746%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEMOSTEMIX INC.	0.00%	0.00%	-40.00%	-40.00%	11.48M
WUXI APPTEC CO., LTD.	-0.25%	-1.36%	+44.08%	+102.76%	68.24B
ARGENX SE	+0.42%	-3.85%	+31.22%	+74.74%	62.23B
INSMED INCORPORATED	-1.18%	+0.47%	-12.78%	+384.69%	27.8B
WUXI BIOLOGICS (CAYMAN) INC.	-1.05%	-4.43%	+30.56%	+10.07%	24.86B
BIONTECH SE	-1.76%	-6.30%	-4.55%	-19.75%	24.22B
GENMAB A/S	+0.22%	-3.79%	+14.36%	-19.64%	19.36B
PHARMAESSENTIA CORPORATION	-1.86%	-2.22%	+202.03%	+353.89%	17.28B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.94%	-4.94%	-5.29%	+495.65%	14.46B
EXELIXIS, INC.	-1.54%	-2.88%	+52.33%	+159.75%	14.23B
Average	-0.90%	-2.97%	+31.19%	+150.21%	27.27B
Weighted average by Cap.	-0.63%	-3.10%	+35.51%	+136.80%

	2024	2025
Net sales	-	-
Net income	-2.62M -1.89M -1.63M -1.54M -1.4M -181M -2.64M -18.3M -7.04M -91.82M -7.11M -6.95M -292M	-4.71M -3.41M -2.93M -2.77M -2.52M -326M -4.76M -32.97M -12.69M -165M -12.81M -12.53M -525M
Net Debt	4.23M 3.06M 2.63M 2.48M 2.26M 293M 4.27M 29.59M 11.39M 148M 11.5M 11.25M 472M	2.86M 2.07M 1.78M 1.68M 1.53M 198M 2.89M 20.01M 7.7M 100M 7.77M 7.6M 319M